Starting a statin when 10-year cardiovascular risk is 7.5% to under 10%

Whether to start a statin to prevent a first cardiovascular event.

Adults aged 40 to 75 with no history of cardiovascular disease, one or more risk factors (dyslipidemia, diabetes, hypertension, or smoking), and an estimated 10-year cardiovascular event risk of 7.5% to less than 10%.

SourcedModeledNo projected outcomes are generated on this page.

What this decision concerns

In this recommendation, the 10-year risk estimate concerns a first major cardiovascular event. The cited US risk estimator uses age, cholesterol, systolic blood pressure, blood-pressure treatment, diabetes, and smoking, with sex- and race-specific equations; its hard outcomes include myocardial infarction or coronary heart disease death and ischemic stroke or stroke-related death. The Task Force stresses that the prediction is an estimate and can be miscalibrated.

SourcedUS Preventive Services Task Force · 2022

The Task Force recommends that clinicians selectively offer a statin to this group, and states that the likelihood of benefit is smaller here than for people whose 10-year risk is 10% or greater.

SourcedUS Preventive Services Task Force · 2022

The options

Start a statin now

Start a statin and keep taking it as ongoing prevention.

For this risk band the Task Force concludes with moderate certainty that statin use has at least a small net benefit for preventing cardiovascular events and all-cause mortality.
Applies to: Adults aged 40 to 75 with a 10-year risk of 7.5% to less than 10% and at least one risk factor.
SourcedUS Preventive Services Task Force · 2022
Across 22 trials, statins were associated with lower all-cause mortality (absolute risk difference -0.35%), fewer myocardial infarctions (-0.85%), fewer strokes (-0.39%), and fewer composite cardiovascular events (-1.28%).
Applies to: Adults without prior cardiovascular events across a range of baseline risk, followed for 6 months to 6 years. These figures are not specific to the 7.5% to under 10% band.
SourcedAgency for Healthcare Research and Quality evidence review for the USPSTF · 2022
The association with cardiovascular mortality was not statistically significant.
Applies to: Same pooled trial population.
SourcedAgency for Healthcare Research and Quality evidence review for the USPSTF · 2022
Statin therapy was not significantly associated with increased serious adverse events, muscle pain, or raised liver enzymes.
Applies to: 22 randomized trials plus 3 observational studies reporting harms.
SourcedAgency for Healthcare Research and Quality evidence review for the USPSTF · 2022
Statin therapy was not significantly associated with increased diabetes risk overall, though one trial found high-intensity statin therapy was.
Applies to: Pooled trials; the high-intensity finding comes from a single trial.
SourcedAgency for Healthcare Research and Quality evidence review for the USPSTF · 2022

Do not start a statin now, and revisit

No statin now. Revisit it as risk factors or preferences change.

The small net benefit the Task Force concludes statin use has for this risk band is forgone.
Applies to: Adults in the 7.5% to under 10% risk band.
SourcedUS Preventive Services Task Force · 2022
For this band the Task Force recommends selectively offering a statin rather than prescribing one for everyone who qualifies.
Applies to: Adults in the 7.5% to under 10% risk band.
SourcedUS Preventive Services Task Force · 2022

Set against what matters to you

Modeled

Read from what you saved on this device.

What sources report about what matters to you

Nothing yet. Mark what matters to you, and anything the sources say about it shows up here.

Pulls in two directions

Nothing so far pulls against anything else.

Still unknown

Nothing is marked as a priority yet, so nothing here is connected to what matters to you. The options and their sources are still readable below.
Not in the sources here.
The Task Force found the evidence insufficient to assess starting a statin for primary prevention in adults 76 years or older, and trial data for people older than 75 were sparse.
US Preventive Services Task Force, 2022 statement
The trials reviewed had 6 months to 6 years of follow-up. The risk threshold the recommendation uses is a 10-year estimate.
Agency for Healthcare Research and Quality evidence review for the USPSTF, 2022 statement
Your own 10-year risk estimate comes from a calculator applied to your measurements. Neither the estimate nor how it was produced is carried in this record.
Not in the sources here.
What ongoing statin treatment would involve for you day to day, including monitoring, cost, and interaction with other medicines, is not carried in this record.
Not in the sources here.

Worth asking

What is my estimated 10-year risk, which calculator produced it, and what went into it?
What would starting a statin involve for me: dose, monitoring, cost, and other medicines I take?
What would we watch for, and when would we reconsider this?
What non-medication steps would change my risk, and by how much?

Start with what matters

How this measures up

Checked against IPDAS 5.0: 11 met, 1 partly met, 2 not met

Sets source-backed statements about named options against what the person said matters. Does not meet the development and evaluation standard a patient decision aid requires. Three further stages would be needed to call it a patient decision aid: essential-criteria appraisal, an independent bias appraisal, and an evaluation of what it changes for the people who use it. None has been done. 3 criteria below are not fully met.

Qualifying criteria

MetHealth conditionchecked automatically
A source-backed description of the health condition or event is recorded separately from the option comparison.
MetExplicit decisionchecked automatically
States the decision: "Whether to start a statin to prevent a first cardiovascular event."
MetTarget audiencechecked automatically
Names who this is for: "Adults aged 40 to 75 with no history of cardiovascular disease, one or more risk factors (dyslipidemia, diabetes, hypertension, or smoking), and an estimated 10-year cardiovascular event risk of 7.5% to less than 10%."
MetOptionschecked automatically
2 options, including an explicit wait-or-decline option.
MetBenefitschecked automatically
4 recorded statements read as supporting an option.
MetHarmschecked automatically
3 recorded statements read as burdening an option.
MetValues clarificationrecorded judgment
Absolute effects, the null cardiovascular-mortality finding, adverse events, and daily medication each route to a different priority.

Bias reduction

Partly metBest available evidencechecked automatically
3 primary sources cited, each paraphrased closely. Dated currentness checks found no final newer edition of any source. That remains a negative currentness finding rather than proof that no update is underway.
Not metUser involvement in developmentrecorded judgment
No patient, caregiver, or clinician took part in developing this journey. No usability or comprehension testing has been run on it.
MetNeutral presentation of optionschecked automatically
Every option carries at least one statement in each direction, so no option is recorded as all upside or all downside.
MetComplete citationschecked automatically
3 sources, each with a full citation, a resolving identifier, a publication date, and the date and route it was read.
MetPublication or version datechecked automatically
Last reviewed 2026-09-18.
Not metUpdate policyrecorded judgment
Each journey records when it was last reviewed. A recheck cadence and triggers are proposed, and source recheck due dates are computed from them, but no owner has adopted the policy. This stays unmet until one does.
MetFunding disclosedrecorded judgment
Funding and editorial independence are stated at /independence.

Screening decisions

Not applicableWhat the test measureschecked automatically
This journey is not a screening decision.
Not applicableConsequences of a positive resultchecked automatically
This journey is not a screening decision.
Not applicableNext steps after either resultchecked automatically
This journey is not a screening decision.
Not applicableOverdiagnosis and false positiveschecked automatically
This journey is not a screening decision.

This checks the seven IPDAS 5.0 qualifying criteria, seven bias-reduction criteria, and four screening-specific criteria against what each journey holds. IPDAS 5.0 contains more than these. A criterion absent here has not been assessed and is not passed. Standard: IPDAS 5.0, published 2026-06-12. Assessment is by Values in Care, not by IPDAS or any outside reviewer.

Sources

Sourced

US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753.
https://doi.org/10.1001/jama.2022.13044
Read 2026-09-11 from the PubMed record (structured abstract of the version of record).
Currentness check · 2026-09-13
No later Task Force recommendation statement on statins for primary prevention is indexed in PubMed.
Method: PubMed title search for a later recommendation statement on the same topic, via the PubMed MCP connector.
Not covered: The Task Force's own site lists draft and in-progress topics and was not reachable from the environment where this PubMed-only check ran. A statement in draft would not appear in this search.
Adjacent evidence, not incorporated into this journey: A 2026 randomized trial of statin discontinuation in adults 75 and older (SAGA/SITE, Lancet Healthy Longev 2026;7(7):100884, PMID 42580354) reports that stopping was non-inferior to continuing for 3-year all-cause mortality. It concerns discontinuation rather than starting, so it does not supersede the 2022 statement, and it bears on the uncertainty this journey already records about adults 76 and older. A clinical reviewer should decide whether it belongs in that uncertainty.
Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;328(8):754-771.
https://doi.org/10.1001/jama.2022.12138
Read 2026-09-11 from the PubMed record (structured abstract of the version of record).
Currentness check · 2026-09-13
No later evidence review for this Task Force topic is indexed in PubMed.
Method: PubMed title search for a later recommendation statement on the same topic, via the PubMed MCP connector.
Not covered: The Task Force's own site lists draft and in-progress topics and was not reachable from the environment where this PubMed-only check ran. A statement in draft would not appear in this search.
US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. Final Recommendation Statement. August 23, 2022.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication
Read 2026-09-18 from the USPSTF final recommendation statement (official web page).
Currentness check · 2026-09-18
The Task Force's official page continues to present the 2022 recommendation as its final statin primary-prevention recommendation; no final successor was identified on the checked page.
Method: Direct review of the USPSTF final recommendation page and, where present, the Task Force's in-progress update page.
Not covered: This check establishes what the publisher currently posts. It does not predict the timing or content of a future draft or final recommendation.

Each clinical statement above paraphrases one of these sources closely. Filing it under a priority, or reading it against priorities you saved, is a Values in Care editorial operation rather than a source finding.

Open Source Watch